BCDABioCardia, Inc.
1.010USD+1.92%Mkt Cap: 15.29M $P/E: —3d ago
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is Car…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 BioCardia (BCDA) Q2 2026 Earnings Call Transcript Japan regulatory progress and narrowed losses drive CardiAMP advancement. | ||
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... BioCardia advances toward Japanese Shonin submission and FDA approval pathways while managing cash runway into 2027. | ||
 BioCardia, Inc. Q2 2026 Earnings Call Summary Moby summary of BioCardia, Inc.'s Q2 2026 earnings call | ||
 New Strong Sell Stocks for July 14th AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026. | ||
MMT Newswires | ||
MMT Newswires | ||
MMT Newswires | ||